Business Wire

ESI-GROUP

22.9.2021 14:26:12 CEST | Business Wire | Press release

Share
ESI Group: EMPHYSIS – The Missing Link Between Digital Simulation and Embedded Software

Regulatory News:

ESI Group (Paris:ESI):

The research project EMPHYSIS led by Bosch has delivered the new “eFMI standard” for model exchange to accelerate the model-based development of embedded software. On the 15th of September, this international collaborative project gathering 25 industrial and academic partners from different fields (like automotive and information technologies) situated in Belgium, Canada, France, Germany, and Sweden received the ITEA Award of Excellence for this unique achievement.

Better code with less effort through “eFMI” - the new model-exchange standard for embedded devices

When developing a new function, many engineers learn the hard way that their outstanding knowledge about the physics of their products is not enough by far to develop a function for an embedded target, due to the demanding requirements of safety-critical software, weak CPU magnitude and less memory than expected. While this might result in a never-to-be-realised excellent initial idea of operating and controlling their product in a much smarter way, at the same time it reveals the need for a link between digital simulation of physical processes and embedded software.

The aim of the EMPHYSIS project (Embedded Systems with Physical Models in the Production Code Software), led by Bosch, was to jointly come up with a new open standard that lays the foundation to develop new innovative tools. This that allows model-based functions to be realized directly in embedded software with better code and less effort. For this purpose, the project carried forward the idea of the very successful Functional Mock-up Interface (FMI) model exchange standard for simulation to develop FMI for embedded systems - the new “eFMI standard”. This enables a wide variety of advanced model-based approaches for control and diagnosis, such as solving a set of differential equations to compute a signal instead of measuring it via a sensor. By allowing a hardware sensor to be replaced with a piece of software, we significantly reduce the total cost.

« The EMPHYSIS project has achieved several outstanding results such as the automatic generation of efficient code for embedded devices. It shows the power of collaborative research projects to drive the adoption of a new standard and to generate significant productivity gains for the industry. »

– Jean-François Lavignon, ITEA Vice-chairman

The technical deep dive and benefits

Technically speaking, eFMI is innovative in that it provides a target-independent intermediate format defined by an entirely new language, the Guarded Algorithmic Language for Embedded Control: GALEC. This new programming language is able to guarantee that an algorithm described in this language can be translated into code that has:

  • static worst-case execution time;
  • static a-priori known memory demand; and
  • a statically proven absence of illegal memory access.

In other words: code that satisfies the hard requirements of automotive safety-critical embedded software, which also makes it applicable to many more, less restricted domains like robotics, industrial applications and consumer goods.

With eFMI and GALEC it is now possible to capture the computational essence of a model in a target-independent form that is a solid foundation for any code generator to produce highly optimised code for arbitrary runtime environments and software architectures. All this is cast into a traceable, extendable and verifiable container architecture that goes far beyond a simple exchange format.

The eFMI workflow allows developers to model a system on a higher level of abstraction, starting with a reusable, high-level, component-oriented and physically structured model. The tooling kit then automatically transforms this into a solution which can be better integrated into software.

The main benefits of this solution and the associated eFMI workflow are:

  • accelerating development time;
  • better use of domain experts by separating the concerns of physical modelling and embedded implementation;
  • overcoming vendor lock-in through eFMI being published as an open standard on GitHub; and
  • enabling new ways of OEM supplier collaborations.

Continuous success

An OEM Advisory Board has been established to gather additional requirements, input and use-cases and further disseminate the project’s results, helping to secure uptake and future innovations in new domains.

On 22 March 2021, right after the project’s end, the non-profit Modelica Association officially approved a new project under its umbrella to further develop, standardize and promote eFMI. With Robert Bosch GmbH, Dassault Systèmes, DLR Institute of System Dynamics and Control, dSPACE, ESI Group, ETAS GmbH and Modelon AB as initial members of the steering committee and Mercedes-Benz AG having joined recently, the first official release of eFMI 1.0 is targeted within 2021. Having developed 14 tools within EMPHYSIS, eFMI already has a broad foundation even before its official release.

« What makes us proud as a team is the fact that this success has been recognized not only by our business partners and the OEM Advisory Board representing the voice of the customer, but also by the ITEA organization.»

– Oliver Lenord, Research Engineer at the Model-based Systems Engineering department at Robert Bosch

For society as a whole, EMPHYSIS’ better software translates into safer and more efficient vehicles which are able to keep pace with customer demands and help tackle climate issues in the longer term. For the time being, however, the project’s message is clear: by taking full advantage of an equation-based, component-oriented modelling language with a good library, 90% gains can be made in productivity of model-based function development.

EMPHYSIS project partners

Belgium

  • Dana Belgium
  • Siemens Industry Software NV
  • University of Antwerp NEXOR

Canada

  • Maplesoft

France

  • CEA
  • Dassault Systemes SE
  • FH Electronics
  • Institut Polytechnique de Grenoble
  • OSE Engineering
  • Renault SAS
  • Siemens Industry Software SAS
  • SOBEN

Germany

  • AbsInt Angewandte Informatik GmbH
  • Deutsches Zentrum für Luft- und Raumfahrt (DLR) System Dynamics and Control
  • dSPACE GmbH
  • Elektronische Fahrwerksysteme GmbH
  • ESI ITI GmbH, part of ESI Group
  • ETAS GmbH
  • PIKETEC
  • Robert Bosch GmbH

Sweden

  • Dassault Systèmes AB
  • Linköping University
  • Modelon AB
  • RISE - Research institutes of Sweden SICS East
  • Volvo Personvagnar AB

About ITEA

ITEA is the Eureka Cluster for software innovation, enabling a large international community to collaborate in funded projects that turn innovative ideas into new businesses, jobs, economic growth and benefits for society. https://itea4.org

About ESI Group

Founded in 1973, ESI Group envisions a world where Industry commits to bold outcomes, addressing high stakes concerns - environmental impact, safety & comfort for consumers and workers, adaptable and sustainable business models. ESI provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise to allow industries to make the right decisions at the right time, while managing their complexity. Acting principally in automotive & land transportation, aerospace, defense & naval, energy and heavy industry, ESI is present in more than 20 countries, employs 1200 people around the world and reported 2020 sales of €132.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.

For further information: https://www.esi-group.com/fr .

Follow ESI

http://www.esi-group.com/linkedin
http://www.esi-group.com/facebook
http://www.esi-group.com/twitter
http://www.esi-group.com/youtube

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye